Pfizer's oral antiviral might be better, but Merck still expects $5B-plus from molnupiravir in ...

Retrieved on: 2022-02-03 18:48:10

Tags for this article:

Click the tags to see associated articles and topics

Pfizer's oral antiviral might be better, but Merck still expects $5B-plus from molnupiravir in .... View article details on hiswai:

Excerpt

Despite worries that Merck's oral COVID antiviral is inferior to Pfizer's rival drug, the Merck medicine is seeing demand amid the omicron surge.

Article found on: www.fiercepharma.com